Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
To enhance the pharmacological properties of the ruthenium catalyst, provide cancer selectivity for the treatment, and enable the treatment of challenging hypoxic tumors, the metal complexes were covalently conjugated to the side chains of polymers with a carbon fluorinated moiety that could co-deliver oxygen to the tumor
(Manny) Simons, PhD MBA, CEO and Co-Founder Number of Employees: 100+ Stage: Acquired (by Eli Lilly) Financial Snapshot: Acquisition valued at $610 million ($487 million in cash, plus CVR) Notable Investors: 5AM Ventures, New Enterprise Associates (NEA) Key Products: Akouos does not yet market any products
This review paper summarizes the research findings for NAD+ boosters and brain health, highlighting positive benefits for cognitive function and brain aging in animal models
Gordon S, Pluddemann A, Martinez Estrada F
Muscle Loss and Supportive Care During GLP-1 Receptor Agonist Therapy: A Review. Metabolites , 16(6):364, 2026
US$ 26.39
US$ 22.09
US$ 25.67
US$ 24.08
US$ 29.88
US$ 21.43
